Commercial-stage biopharmaceutical company Bio-Thera Solutions (SH:688177:SH) announced on Thursday that it has signed commercialisation and licence agreements with Dr. Reddy's Laboratories SA, a subsidiary of Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY| NYSE: RDY | NSEIFSC: DRREDDY), for BAT2206, a proposed Stelara biosimilar, and BAT2506, a proposed Simponi biosimilar.

Under the contract Bio-Thera will be responsible for development, manufacturing and supply of BAT2206 and BAT2506, while Dr. Reddy's will seek regulatory approvals and commercialise the product in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand and Vietnam. Dr. Reddy's will also receive the exclusive commercial rights to BAT2206 in Colombia.

Stelara is a human monoclonal antibody used for the treatment of Crohn's disease, ulcerative colitis (UC), plaque psoriasis and psoriatic arthritis.

Simponi is a human monoclonal antibody indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and UC.